# Focal Mass Drug Administration for the Prevention of Malaria in Pregnancy

> **NCT07021430** · EARLY_PHASE1 · NOT_YET_RECRUITING · sponsor: **University of North Carolina, Chapel Hill** · enrollment: 300 (estimated)

## Conditions studied

- Malaria Prevention

## Interventions

- **DRUG:** Dihydroartemisinin Piperaquine

## Key facts

- **NCT ID:** NCT07021430
- **Lead sponsor:** University of North Carolina, Chapel Hill
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-04
- **Primary completion:** 2028-04
- **Final completion:** 2028-04
- **Target enrollment:** 300 (ESTIMATED)
- **Last updated:** 2026-02-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07021430

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07021430, "Focal Mass Drug Administration for the Prevention of Malaria in Pregnancy". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07021430. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*